ReviewWorld journal of gastroenterology2011
Pathologic pancreatic endocrine cell hyperplasia.
Review in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 61 citations in OpenAlex.
- A 30-year institutional experience of insulinoma management at a tertiary care center: a case series.Gland surgery · 2026Article
- Characterization of small intestinal neuroendocrine tumorlets.Endocrine-related cancer · 2026Article
- Identifying intact and fibrotic parenchyma in pancreatic ductal adenocarcinomas using compression optical coherence elastography.Scientific reports · 2026Article
- Recent advances in pancreatic α-cell transdifferentiation for diabetes therapy.Frontiers in immunology · 2025Review
- Genotype-histotype-phenotype correlations in hyperinsulinemic hypoglycemia.Histology and histopathology · 2024Review
- Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report.Frontiers in endocrinology · 2024Article
- Review
- Sudden 'cure' of type two diabetes due to pancreatic insulinoma: A case report.Molecular and clinical oncology · 2020Article
- Pathological Mechanisms in Diabetes of the Exocrine Pancreas: What's Known and What's to Know.Frontiers in physiology · 2020Review
- Pancreatic Islet Hyperplasia: A Potential Marker for Anabolic-Androgenic Steroid Use.Academic forensic pathology · 2018Article
- Lineage conversion of mouse fibroblasts to pancreatic α-cells.Experimental & molecular medicine · 2017Article
- Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma.Journal of surgical case reports · 2016Article
- Spontaneous hypoglycemia: diagnostic evaluation and management.Endocrine · 2016Article
- Elusive liver factor that causes pancreatic α cell hyperplasia: A review of literature.World journal of gastrointestinal pathophysiology · 2015Review
- Hyperplasia to neoplasia sequence of duodenal and pancreatic neuroendocrine diseases and pseudohyperplasia of the PP-cells in the pancreas.Endocrine pathology · 2014Review
- Pancreatic neuroendocrine tumors: biology, diagnosis,and treatment.Chinese journal of cancer · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathologic hyperplasia of various pancreatic endocrine cells is rare but has been long known. β cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia of infancy, which is commonly caused by mutations in the islet ATP-sensitive potassium channel, and to non-insulinoma pancreatogenous hypoglycemia in adults, which may or may not be associated with bariatric surgery. α cell hyperplasia may cause glucagonoma syndrome or induce pancreatic neuroendocrine tumors. An inactivating mutation of the glucagon receptor causes α cell hyperplasia and asymptomatic hyperglucagonemia. Pancreatic polypeptide cell hyperplasia has been described without a clearly-characterized clinical syndrome and hyperplasia of other endocrine cells inside the pancreas has not been reported to our knowledge. Based on morphological evidence, the main pathogenetic mechanism for pancreatic endocrine cell hyperplasia is increased endocrine cell neogenesis from exocrine ductal epithelium. Pancreatic endocrine cell hyperplasia should be considered in the diagnosis and management of hypoglycemia, elevated islet hormone levels, and pancreatic neuroendocrine tumors. Further studies of pathologic pancreatic endocrine cell hyperplasia will likely yield insights into the pathogenesis and treatment of diabetes and pancreatic neuroendocrine tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.